LABORATORIES AND RESEARCH

Header

WHERE MEDICAMENTS WITHOUT SIDE EFFECTS ARE PRODUCED

Our production unit is authorized in accordance with international GMP standards. The production, control and storage of products take place in controlled particle contamination rooms, according to the strictest international standards.

As regards low dose medicinal products, the production starts from the mother tincture, a special macerate that can be obtained from plants, buds, biochemical compounds or biological substances, according to the ancient preparation procedures of the traditional Homeopathic Pharmacopoeia.

The mother tincture is gradually and constantly diluted under a laminar flow hood in class 100, usually using a water-alcohol solution as a solvent.

At each dilution a dynamization procedure is performed, i.e., one vertical shaking that transmits physical-chemical specifications to the solution. The activation process is standardized through the use of the SKA (Sequential Kinetic Activation) method, designed and developed by our researchers.

This technique ensures a full bioavailability of the active ingredients and improves their therapeutic properties.

Guna produces pellets, globules and drops for oral use, as well as injectable vials.

The production line is fully automated and produces both mono- and multi-component remedies.

All the qualitative, quantitative and microbiological controls required by the regulations on medicaments are carried out at our perfectly equipped production site. Guna, in an ideal synthesis between tradition and modernity, uses the most advanced scientific and technological breakthroughs in the production of its medicines, to give doctors and patients more and more effective medicaments without side effects, in compliance with the human being’s uniqueness.

In order to improve more and more the efficacy of our medicaments we are continuously developing basic and clinical researches. In the follow you may read some references of the publication supported by GUNA.

PUBLISHED PAPERS

Year

Authors

Journal

Research type

Title

Tested Molecules

2009

Gariboldi S. et al.

Pulmonary Pharmacology & Therapeutics

In vivo

basic

research

Low dose oral administration of cytokines for treatment of allergic asthma.

IL-12

IFN-γ

2012

D’amico L. et al.

Journal of Cancer Therapy

Ex vivo

basic

research

Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non Small Cell Lung Cancer Patients.

IL-12

2013

Cardani D. et al.

Gastroenterology Research

In vivo

basic

research

Oral administration of Interleukin-10 and Anti-IL-1 Antibody ameliorates experimental intestinal inflammation.

IL-10

α-IL-1

2014

Radice E.

et al.

International Immunopharmacology

Ex vivo

basic

research

Low-doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study.

IFN-γ

2014

Roberti ML. et al.

Journal of Biological Regulatory & Homeostatic Agents

Clinical Trial

Immunomodulating treatment with low dose Interleukin-4, Interleukin-10 and Interleukin-11 in Psoriasis Vulgaris.

IL-4

IL-10

IL-11

2015

Luchetti P.

Minerva Medica Oftalmologica

Clinical

Trial

Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine.

Monocentric retrospective observational study.

NT3

NT4

NGF

2015

Barygina V.

et al

Journal of Dermatological Science

In vitro

Basic research

Treatment with low-dose cytokines reduces oxidative-mediated injury

in perilesional keratinocytes from vitiligo skin.

IL-4

IL-10

b-FGF

β-endorphin

2015

Lotti T.

et al

Journal of

Biological Regulatory

& Homeostatic Agents

Clinical Trial

Vitiligo: successful combination treatment based on oral low dose cytokines and

di­fferent topical treatments.

IL-4

IL-10

Anti-IL-1

b-FGF

2015

Radice E.

et al

Translational

oncology

Ex vivo

Basic research

Enhancement of the immunomodulatory functions of ex vivo-generated dendritic cells from early-stage colon cancer patients by consecutive exposure to low doses of sequential kinetic activated IL-4 and IL-12.

A preliminary study.

IL-4

IL-12

2015

Lotti T.

et al

Der Hautarzt

Clinical Trial

Successful combination treatment for Psoriasis with phototherapy and Low Dose Cytokines. A spontaneous observational retrospective clinical study.

IL-4

IL-10

Anti-IL-1

2015

Tessaro et al.

Journal of Ovarian Research

In vivo

basic

research

Effect of oral administration of low-dose

follicle stimulating hormone on hyperandrogenized

mice as amodel of polycystic ovary syndrome

FSH

2016

 

Barygina V. et al.

 

Journal of Dermatological Science

 

In vivo

basic

research

 Low dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients.  

IL-4

IL-10

b-FGF

beta-Endorphin

2016

 

Fiorito F. et al.

 

Comparative Immunology, Microbiology and Infectious Diseases

 

Clinical Trial (veterinary)

 

Clinical improvement in feline herpesvirus 1 infected cats by oral lowdose of interleukin-12 plus interferon-gamma.

IL-12

IFN-γ

 

2016

 

Genazzani A. et al

 

Frontiers in Gynecological Endocrinology

   

Pharmacological and Integrative  Treatment of Stress-Induced Hypothalamic Amenorrhea.

Beta-Estradiol

 

2016

 

Molinari C. et al

 

Cells Tissues Organs

Basic in vitro research

Stimulation of the Non-neuronal Cholinergic System by Highly Diluted Acetylcholine in Keratinocytes.

 
Acetylcholine

2017

Martin martin S. et al.

Drud Design, Development and Therapy

Clinical Trial

An open randomized active-controlled clinical trial with low-dose SKAcytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.

Anti IL-1

IL-10

IL-4

 

2017

Galli E. et al.  Italian Journal of Pediatrics

Clinical Trial

Clinical and immunological evaluation of a long-term treatment with Low Dose Medicine in pediatric population affectes by chronic Atopic Dermatitis. Double-blind, randomized two-stage clinical trial.

IL-12

INF-Υ

 

SUBMITTED PAPERS

Year

Authors

Journal

Research type

Title

Tested Molecules

2016

De Cicco F. et al.

 

Basic in vitro and in vivo research

Efficacy of low-dose SKA cytokines and hormones in the treatment of endometriosis in an animal model and in cell cultures.

Anti IL-1

IL-10

Progesteron

2016

Matucci Cerinic M. et al.

 

Clinical trial

Evaluation of the efficacy of low-dose SKA anti-IL-1 and IL-10 in early stage symptomatic hand and knee osteoarthritis. Evaluation of the efficacy of low-dose SKA anti-IL-1 in chronic gout.

Anti IL-1

IL-10

2017

Martin martin S. et al.

 

Clinical Trial

An open randomized active-controlled clinical trial with low-dose SKAcytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.

Anti IL-1

IL-10

IL-4

2017

 

Carello R. et al.

   

Clinical Trial

 

Long-term treatment with Low-Dose Medicine in chronic childhood eczema. A double-blind two-stage randomized control trial.

 

IL-12

IFN-γ

 

RESEARCH WORKS ON GOING

Year

Authors

Journal

Research type

Title

Tested Molecules

2017

Fiorillo A.

 

Basic  research

Evaluation of the effects of low-dose SKA interleukins and growth factors on skin ageing

Anti-IL-1

IL-10

IL-4

FGF

PFGF

EGF

TGF-beta

 

RESEARCH WORKS IN PIPELINE

Year

Authors

Journal

Research type

Title

Tested Molecules

2016

Torta R. et al.

 

Clinical

Trial

Fibromyalgia and low grade inflammation: effectiveness and safety of low dose Interleukin-10 in a double blind randomized placebo controlled clinical trial.

IL-10

2016

Masieri S. et al.

 

Clinical Trial

Effects of low dose SKA Interleukin-10 and TGF-Beta in nasal polyps.

IL-10

TGF-β

2016

De Cicco F. et al.

 

clinical trial

Efficacy of low dose SKA interleukins and hormones in Endometriosis. Prospective, randomized, multicenter, active-control clinical trial.

Anti IL-1

IL-10

Progesteron